Fig. 5: Immune infiltration and immunotherapy response in MOFS subtypes. | Nature Communications

Fig. 5: Immune infiltration and immunotherapy response in MOFS subtypes.

From: Multimodal fusion of radio-pathology and proteogenomics identify integrated glioma subtypes with prognostic and therapeutic opportunities

Fig. 5

A–C Tumor purity, ImmuneScore, and StromalScore across MOFS subtypes, showing lower tumor purity but higher immune and stromal components in MOFS3 (n = 116). Statistic tests: two-sided t test. Data are presented as box plots, with the center line representing the median, the box indicating the interquartile range (IQR, from the 25th to the 75th percentile), and the whiskers extending to the most extreme data points within 1.5 times the IQR; points beyond this range are shown as individual outliers. D Heatmap of immune cells and immunomodulators, indicating higher abundance in MOFS3, highlighting its TME-rich features (n = 116). E–G Infiltration levels of neurons, astrocytes, and oligodendrocytes, with higher levels observed in MOFS1 (n = 116). Statistic tests: two-sided t test. Data are presented as box plots, with the center line representing the median, the box indicating the IQR (from the 25th to the 75th percentile), and the whiskers extending to the most extreme data points within 1.5 times the IQR; points beyond this range are shown as individual outliers. H Immunogram of the cancer-immunity cycle, showing high activation of immune pathways in MOFS3, suggesting greater immunotherapeutic potential. I Activity of MOFS subtypes in GBM patients who received anti-PD-1 immunotherapy, with higher MOFS3 activity in responders. J Comparison of MOFS subtype activity between immunotherapy responders and non-responders (n = 17). Statistic tests: two-sided t test. Data are presented as box plots, with the center line representing the median, the box indicating the IQR (from the 25th to the 75th percentile), and the whiskers extending to the most extreme data points within 1.5 times the IQR; points beyond this range are shown as individual outliers. K Distribution of MOFS subtypes among responders and non-responders to anti-PD-1 therapy, with MOFS3 showing higher response rates. L Kaplan-Meier survival curves stratified by stroma abundance within MOFS3, showing significant prognostic differences between high and low stroma groups. Statistic tests: log-rank test. M ROC analysis of stromal markers, with S100A4 demonstrating predictive ability for stroma abundance at both mRNA and protein levels. N IHC results of S100A4 expression, indicating higher levels in MOFS3 (n = 15).

Back to article page